Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

Ocio Enrique M.; Rosinol Laura; Grande Marta; Ruiz-Zorrilla Ana; Fernandez Alonso; Montoto Carmen

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

【24h】

Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

机译：西班牙复发和/或难治性多重骨髓瘤（RRMM）患者的社会人口统计特征和社会观点：Charismma研究的临时分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共3页
作者
Ocio Enrique M.; Rosinol Laura; Grande Marta; Ruiz-Zorrilla Ana; Fernandez Alonso; Montoto Carmen;
展开▼
作者单位

Univ Salamanca Hosp Univ Salamanca IBSAL Ctr Invest Canc IBMCC CSIC Salamanca Spain;

Hosp Clin Barcelona Josep Carreras Res Inst Hematopoiet Stem Cell Transplantat Unit Hematol Dept;

Takeda Farmaceut Espana SA Med Dept Madrid Spain;

Takeda Farmaceut Espana SA Med Dept Madrid Spain;

Takeda Farmaceut Espana SA Med Dept Madrid Spain;

Takeda Farmaceut Espana Madrid Spain;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study [J] . Ocio Enrique M., Rosinol Laura, Grande Marta, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：西班牙复发和/或难治性多重骨髓瘤（RRMM）患者的社会人口统计特征和社会观点：Charismma研究的临时分析
2. ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update [J] . Pour Ludek, Efebera Yvonne A., Granell Miquel, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：锚（OP-104）对Melflufen和Dexamethasone的研究与含有复发/难治多骨髓瘤（RRMM）难以解决的患者（RRMM）难以解决含有IMID和/或蛋白酶体抑制剂（PI）：第1阶段更新
3. HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety [J] . Richardson Paul G., Oriol Albert, Larocca Alessandra, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：Horizo n（OP-106）研究Melflufen在患者中复发/难治多骨髓瘤（RRMM）难以解决Daratumumab和/或pomalidomide：更新的疗效和安全性
4. Analysis of the secondary structure of blood serum proteins from patients with multiple myeloma [C] . M O Kobeleva, E A Telnaya, L V Plotnikova, International Conference PhysicA.SPb . 2020

机译：多发性骨髓瘤患者血清血清蛋白二次结构分析
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. Successful identification of predictive profiles for infection utilising systems‐level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma [O] . Marcel Doerflinger, Alexandra L Garnham, Saskia Freytag, 2021

机译：利用系统级免疫分析的感染预测性谱的成功鉴定：复发和难治性多发性骨髓瘤患者的试验研究
7. Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR [O] . K. Weisel, A. Palumbo, A. Chanan-Khan, 2016

机译：患者（PTS）中达拉姆宫，硼替佐米和地塞米松（DVD）和硼替米布（DVD）和地塞米松（VD）的第3阶段随机研究，复发或难治多骨髓瘤（RRMM）：蓖麻

Socio-Demographic Features and Societal Perspective of Relapse and/or Refractory Multiple Myeloma (RRMM) Patients in Spain: An Interim Analysis of Charismma Study

著录项

相似文献

相关主题

期刊订阅